4-Mar-2026 3:02 PM CST - Business Wire Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025 $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced its fourth quarter and fiscal year 2025 financial results. Fourth Quarter 2025 Financial Highlights Compared to Prior Year Quarter Total net sales increased 16% to $33.8 million, with Tru Niagen sales of $27.5 million, up 21% from the prior year quarter. Gross margin increased 160 basis points to 64.1%. Net income of $4.1 million compared to $7.2 million in the prior year quarter. Q4 2024 benefited from a $3.5
6-Feb-2026 7:32 AM CST - Business Wire Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026 $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, March 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year 2025, which ended December 31, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wed
4-Nov-2025 3:02 PM CST - Business Wire Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the third quarter of 2025. Third Quarter 2025 Financial Highlights Compared to Prior Year Period Total net sales increased 33% to $34.0 million, with Tru Niagen sales of $26.0 million, up 44%. Gross margin increased 100 basis points to 64.5%. Sales and marketing expense as a percentage of net sales was 25.8%, an improvement of 170 basis points. Net income of $4.6 million or $0.06 earnings
21-Oct-2025 7:32 AM CST - Business Wire Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Tuesday, November 4, 2025, at 4:30 p.m. ET to discuss its financial results for the third quarter 2025, which ended September 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Tuesday, November
6-Aug-2025 3:02 PM CST - Business Wire Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the second quarter of 2025. Second Quarter 2025 Financial Highlights Compared to Prior Year Period Total net sales increased 37% to $31.1 million, with Tru Niagen sales reaching $22.7 million, growing 22%. Niagen ingredient sales increased 135% to $7.4 million including food-grade and pharmaceutical-grade. Gross margin increased 480 basis points to 65.0%. Sales and marketing expense as a
4-Aug-2025 7:32 AM CST - Business Wire Niagen Bioscience to Present at Canaccord Genuitys 45th Annual Growth Conference $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuitys 45th Annual Growth Conference, taking place from August 12 to 14, 2024, in Boston. Mr. Fried is scheduled to participate in a fireside chat on Tuesda
23-Jul-2025 7:34 AM CST - Business Wire Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, August 6, at 4:30 p.m. ET to discuss its financial results for the second quarter 2025, which ended June 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on W
4-Jun-2025 7:32 AM CST - Business Wire Niagen Bioscience to Present at Oppenheimers 25th Annual Consumer Growth and E-Commerce Conference $NAGE #InvestorRelations--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Oppenheimers 25th Annual Consumer Growth and E-Commerce Conference. Mr. Fried is scheduled to participate in a fireside chat on Monday, Jun 9, from 2:15 p.m. to 2:50 p.
7-May-2025 3:02 PM CST - Business Wire Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2025. First Quarter 2025 Financial and Recent Operational Highlights Total net sales were $30.5 million, with $21.5 million from Tru Niagen, up 38%, and 24%, respectively, from the prior year quarter. Total Niagen ingredient sales, including food-grade and pharmaceutical-grade, reached $8.0 million, up 95% YoY. Delivered strong gross margin of 63.4%, up 270 basis poin
4-Mar-2026 3:02 PM CST - Business Wire Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025 $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced its fourth quarter and fiscal year 2025 financial results. Fourth Quarter 2025 Financial Highlights Compared to Prior Year Quarter Total net sales increased 16% to $33.8 million, with Tru Niagen sales of $27.5 million, up 21% from the prior year quarter. Gross margin increased 160 basis points to 64.1%. Net income of $4.1 million compared to $7.2 million in the prior year quarter. Q4 2024 benefited from a $3.5
6-Feb-2026 7:32 AM CST - Business Wire Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026 $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, March 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year 2025, which ended December 31, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wed
4-Nov-2025 3:02 PM CST - Business Wire Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the third quarter of 2025. Third Quarter 2025 Financial Highlights Compared to Prior Year Period Total net sales increased 33% to $34.0 million, with Tru Niagen sales of $26.0 million, up 44%. Gross margin increased 100 basis points to 64.5%. Sales and marketing expense as a percentage of net sales was 25.8%, an improvement of 170 basis points. Net income of $4.6 million or $0.06 earnings
21-Oct-2025 7:32 AM CST - Business Wire Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Tuesday, November 4, 2025, at 4:30 p.m. ET to discuss its financial results for the third quarter 2025, which ended September 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Tuesday, November
6-Aug-2025 3:02 PM CST - Business Wire Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the second quarter of 2025. Second Quarter 2025 Financial Highlights Compared to Prior Year Period Total net sales increased 37% to $31.1 million, with Tru Niagen sales reaching $22.7 million, growing 22%. Niagen ingredient sales increased 135% to $7.4 million including food-grade and pharmaceutical-grade. Gross margin increased 480 basis points to 65.0%. Sales and marketing expense as a
4-Aug-2025 7:32 AM CST - Business Wire Niagen Bioscience to Present at Canaccord Genuitys 45th Annual Growth Conference $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuitys 45th Annual Growth Conference, taking place from August 12 to 14, 2024, in Boston. Mr. Fried is scheduled to participate in a fireside chat on Tuesda
23-Jul-2025 7:34 AM CST - Business Wire Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, August 6, at 4:30 p.m. ET to discuss its financial results for the second quarter 2025, which ended June 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on W
4-Jun-2025 7:32 AM CST - Business Wire Niagen Bioscience to Present at Oppenheimers 25th Annual Consumer Growth and E-Commerce Conference $NAGE #InvestorRelations--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Oppenheimers 25th Annual Consumer Growth and E-Commerce Conference. Mr. Fried is scheduled to participate in a fireside chat on Monday, Jun 9, from 2:15 p.m. to 2:50 p.
7-May-2025 3:02 PM CST - Business Wire Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2025. First Quarter 2025 Financial and Recent Operational Highlights Total net sales were $30.5 million, with $21.5 million from Tru Niagen, up 38%, and 24%, respectively, from the prior year quarter. Total Niagen ingredient sales, including food-grade and pharmaceutical-grade, reached $8.0 million, up 95% YoY. Delivered strong gross margin of 63.4%, up 270 basis poin
